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Abstract 
Histamine is a monovalent cationic biological amine synthesized by professional 
and non-professional histamine producing cells, which form two distinct cell 
categories. Professional cells produce, store and burst release their histamine 
from storage granules so that locally and temporarily for short periods high 
micromolar histamine concentrations are achieved. Non-professional cells 
generally produce and release histamine into the cytoplasm continuously 
without intermediated storage, to release it along its concentration gradient via 
histamine channels. These channels might play an important role in balancing, 
maintaining and regulating low-level histamine fluctuations, which tend to occur 
due to variation in the histamine content of the food, histamine production by 
microflora, histamine release from professional cells and enzymatic degradation 
and reuptake of histamine. 
Effects of the professionally-produced high histamine levels are mediated 
via two low-affinity histamine receptors, H1R and H2R. In contrast, the non-
professionally-produced, low nascent histamine levels are only able to activate 
two novel high-affinity histamine receptors, H3R and H4R. The former are active 
during short-term emergency “on-state” whereas the latter are active during a basic 
or long term homeostatic “off-state”. Micromolar histamine/H1R/H2R amplifies 
expulsion of irritants (e.g. pollen, helminths) by adding to a direct irritant-induced 
Brought to you by | Università degli Studi di Firenze
Authenticated
Download Date | 11/4/16 12:35 PM
Histamine H4 Receptor:
A Novel Drug Target in Immunoregulation and Inflammation
2 0 2 Chapter 7
reaction an amplifying IgE-dependent immunological component. Nanomolar 
histamine/H3R/H4R seems to participate in dendritic cell-mediated antigen (Ag) 
presentation to T-cells in induction of self-tolerance, sensitization phase in allergy 
and delayed lymphocyte-mediated immune reactions. From this point of view, it 
is interesting that H4R is best known for being expressed by myelopoietic cells, 
such as dendritic cells and lymphocytes, but also polymorphonuclear neutrophils, 
basophils, eosinophils and mast cells (MC). 
The role of histamine has been mainly recognized during exacerbation of 
asthma, allergic rhinitis and conjunctivitis, urticaria and anaphylaxis as well as 
gastric acid secretion after a meal. Antihistamines are generally helpful during 
the acute stages of various allergic states associated with burst release of 
histamine. However, it seems that the basis of these conditions lies in a steadier 
underlying immune activity, e.g. Ag presentation by dendritic cells to T-cells and 
T-cell help to B-cell-dependent IgE immunoglobulin synthesis against T-cell-
dependent Ag. Normally this system participates in the maintenance of health 
(immune tolerance and immune responses against pathogens), but in patients 
it can participate in the initiation and perpetuation of diseases and contributes 
to the recurrence of the symptoms and signs upon renewed exposure to the 
symptom triggers (allergens in allergies and auto-Ag in autoimmune diseases). 
Therefore, antihistamines or H1R-antagonists and H2R blockers provide limited 
therapeutic effectiveness in such conditions, but these conditions may in part be 
regulated by low histamine and high- affinity histamine receptors, in particular 
H4R. Histamine H4R modulation by small molecules administered perorally 
or locally might provide effective and affordable new remedies for various 
autoinflammatory, allergic and autoimmune diseases. 
7.1. Introduction
Despite intense research efforts in the past, new observations on its fundamental 
function have recently been made regarding two intimately interrelated 
concepts, its non-professional synthesis and its novel high-affinity receptors.
The so-called “professional” histamine producing cells produce histamine 
rapidly in copious amounts and store it in storage granules, from which histamine 
and other granular contents can be rapidly released by exocytosis in a process that 
is generally regulated but sometimes apparently stochastic. “Non-professional” 
histamine producing cells generates histamine at a 100- to 1000-fold lower pace 
and release it directly to the cell cytoplasm without an intermediate storage stage. 
Thus, during the “off-state” they first produce histamine in the cytoplasm and then 
passively release it to the extracellular space along the concentration gradient, 
apparently at the same pace as it is produced. This histamine release is mediated 
by “equilibrative uniporter” histamine channels.
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Apart from rapid, temporary and robust local histamine release or slow, low 
level constitutive histamine release, histamine uptake via these “equilibrative 
uniporters” is possible as well. 
Extracellular burst-released micromolar histamine exerts it effects on 
histamine target cells via classical, low-affinity H1R and H2R receptors. In contrast, 
basal non-professional histamine exerts its effects directly only via high-affinity 
H3R and H4R receptors. 
During MC activation and the high histamine “on-state”, the classical 
histamine receptors are rapidly desensitized based on phenomena like receptor 
phosphorylation, G-protein uncoupling, receptor internalization and receptor 
gene transcription. At the same time, the numerous non-professional histamine 
producing cells assume an alternative histamine N-methyl transferase (HNMT)-
depedent function as high-capacity histamine sinks, removing histamine 
effectively from the extracellular space for cytoplasmic degradation. These novel 
cells now work, not to maintain but to return back to the homeostatic nanomolar 
histamine concentrations. However, it is not clear how the histamine-sensitive, 
high-affinity histamine receptors cope with the excessive overstimulation during 
the local and temporary high histamine on-states. 
7.2. Histamine
In human cells, histamine is synthesized from the essential amino acid (AA) 
L-histidine and this synthesis is dependent on L-histidine decarboxylase (HDC). 
Histamine release occurs either via exocytosis or passively via histamine channels. 
Exocytotic release is regulated and occur only after stimulation by allergens, 
substance P as well as other tachykinins, lectin-like structures, physical forces 
(mechanical stimulation) and various foodstuffs such as citrus fruit, strawberries 
and nuts (for a more complete list, see Maintz & Novak 1999). In addition, other 
food itemssuch as such as various fishes (mackerel, herring, sardine, tuna etc.), 
cheeses (Emmental, Swiss, Cheddar, Camembert) and alcohol (in particular red 
wine) also contain histamine. Human bodyis an ecosystem, which contains 10 
times as many bacteria as it contains human cells, so the relase of histamine 
synthesized by intestinal bacterial flora can greatly contribute to physiological 
histamine concentrations. The latter source is notable because it suggests that 
HDC knockout mice are not “histamine-free”.
7.2.1. Histamine Synthesis
It was traditionally thought that MC, basophils, enterochromaffin-like (ECL) cells 
and histaminergic neurons loaded with histamine-containing secretory granules 
were also responsible for histamine synthesis in the human body. It has since 
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been noted that histamine is an important immunomodulatory agent already at 
low nanomolar concentrations, and that leukocytes other than MC and basophils 
can also produce histamine, albeit at a much smaller scale. Furthermore, 
dendritic cells (DC), T-cells, monocyte/macrophages and neutrophils also 
produce histamine (Tanaka & Ichikawa 2011; Kubo & Nakano 1999; Szeberényi 
et al. 2001). Even non-immune cells such as fetal liver cells, ductal epithelial 
cells of the salivary glands, sperm cells, epithelial cells of the mammary glands 
and skeletal muscle cells can synthesize histamine. This suggests that histamine 
has numerous previously undiscovered physiological and pathological effects, 
apparently mediated by the recently discovered H3R and H4R receptors. 
Accordingly, it has been proposed that histamine can maintain homeostasis 
of salivary glands, stimulate neonatal hematopoiesis, regulate reproductive 
organs and improve adaptation of muscle cells to exercise (Tanaka & Ichikawa 
2011; Niijima-Yaoita et al. 2012). Thus, the cells can be divided to two different 
categories: professional and non-professional histamine producing cells 
(Table 7.1), which essentially utilize two different sets of receptors, secretory and 
intake pathways to regulate very different sets of bodily events. 
The molecular basis of professional large scale histamine synthesis and non-
professional small scale histamine synthesis as well as the differences between 
each process has been investigated, where at least two functionally relevant 
isoforms of HDC have been reported (Ichikawa et al. 2010; Tanaka & Ichikawa 
2011). The full-length, low-activity 74-kDa HDC is in professional histamine 
producing cells proteolytically cleaved to a 53-kDa isoform, which is 100-1000-
fold more active than its full-length precursor. In non-professional histamine 
producing cells the full-length post-translational 74 kDa isoform with a low 
enzymatic activity produces histamine to the cell cytoplasm (Tanaka & Ichikawa 
2011; Kubo & Nakano 1999). The activity of this low activity HDC in non-
professional, low scale histamine producing cells is not particularly stable in this 
transformation, but is known to be regulated at the transciptional and protein 
levels by various cytokines, including IL-1, IL-3, IL-12, IL-18, GM-CSF and TNF-α 
(Jutel et al. 2009). HDC activity changes in various infections, inflammation and 
the rejection of transplanted organs. 
7.2.2. Histamine Release
Professional histamine producing cells store histamine in cytoplasmic secretory 
granules. Histamine in these granules is stored by ionic linkage to the carboxyl 
groups of proteins and heparin. A murine connective tissue MC contains 
10-30 pg histamine per cell compared to < 0.2 pg histamine per cell in a mucosal 
MC. If 110 pg/ml of histamine is equivalent to 1 nM, it can be calculated that 
~18500 connective tissue MCs could release enough histamine to 1 mL to reach 
50 μM. Given that 104-105 MCs can be isolated from one gram of human tissues, 
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MCs can have the capacity to produce micromolar histamine concentrations in 
tissues. However, even in optimally timed plasma samples from patients with 
anaphylaxis, histamine levels may be within normal limits (Simons et al. 2008). 
At present, there is lack of technological in vivo histamine sensors which could 
continuously follow locally histamine concentrations in human tissues. Histamine 
burst by exocytosis release can be triggered bysuch as neuropeptides, some 
food items, helminths, mechanical stimulation, wounding or allergic reactions. 
It can lead to micromolar histamine concentrations, as estimated through the 
pKi values of H1R (4.2) and H2R (4.3), of up to 50-100 μM (Lim et al. 2005), 
although the local and temporary nature of professional histamine release and 
1Mechanical, HA releasing foods, lectins, substance P and other tachykinins, allergens (acting on IgE-
sensitized cells)
2Organic cation transporter 2 (OCT2, SLC22A2), organic cation transporter 3 (OCT3, SLC22A3), plasma 
membrane-associated monoamine transporter (PMAT, SLC29A3, equilibrative nucleoside transporter 
3/ENT3) are potential candidates 
3Diamine oxidase
4Histamine N-methyl transferase
5Vesicular monoamine transporter 2
Property Non-professional cells Professional-cells
Rate of HA synthesis Slow 100-1000 times faster
HA synthesizing enzyme 74-kD HDC 53-kD HDC
Handling of synthesized HA Released to the cytoplasm Stored in secretory granules
Requirement for release
Concentration gradient, need 
to overcome the resting cell 
membrane potential 
Stimulus required1
Release of HA
Passively along the 
concentration gradient via 
equilibrative uniporters2
Actively via exocytosis
HA concentrations attained Nanomolar Micromolar
Concentration range Probably very narrow First very high, then rapidly falling off
HA concentration modulation 
in the active concentration 
range
HA from food and microbes Burst release from professional cells
Spatial range Universally present in the body Usually local, at the hot spot
Time range Long-term Short-term
Active during “Off-state” (most of the time) “On-state” (short bursts)
Receptors utilized High affinity H3R, H4R Low affinity H1R, H2R (H3R, H4R)
Handling of extracellular HA 
excess
Degradation by DAO3,uptake via 
equilibrative uniporters1
Degradation by DAO3, uptake 
via equilibrative uniporters1
Handling of HA taken up Degradation by HNMT4 Reuptake to granules by VMAT5
Table 7.1 
Comparison of non-professional and professional histamine (HA) producing cells.
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its subsequent rapid degradation and dilution are reflected in the relatively low 
0.6 µM concentration measured in bronchoalveolar lavage fluid after Ag 
challenge (Calhoun et al. 1998).
Non-professional histamine producing cells produce and secrete 100- to 
1000-fold lower concentrations of histamine and their histamine release (or 
uptake) is mainly driven along the concentration gradient between the intra- and 
extracellular space (Jutel et al. 2009; Tanaka & Ichikawa 2011; Kubo & Nakano 
1999). Effective concentrations at this low histamine level are nanomolar, again 
mainly estimated through the pKi values of H3R (8.0) and H4R (8.2).
7.2.3. Histamine Receptors in General
Histamine affects cells via four histamine receptors which all belong to the large 
G-protein-coupled receptor (GPCR) family. These receptors contain extracellular, 
transmembrane and intracellular domains where the ligand-binding structures 
are located on the extracellular part of the receptor molecule. The intracellular 
domain of the receptor binds various G-proteins which are dependent on 
the receptor and cell type. Thus, G-proteins mediate the extracellular signals 
affecting the extracellular part of the receptor intracellularly via downstream 
activation and/or inhibition of various intracellular signal transduction cascades. 
This ultimately leads to various rapid events such as release of intracellular 
calcium stores and the phosphorylation ordephosphorylation of proteins as well 
as additional slow changes in gene transcription events.
7.2.3.1. Histamine H1 receptors
Although the first antihistamines, were regularly used by the 1940s, it took 
until 1966 before Ash et al. introduced the term H1R to describe a subgroup of 
histamine sensitive receptors which could be blocked by the first generation 
antihistamines or H1R-antagonists (Ash & Schild 1966). Since H1R-antagonists 
only inhibited some of the histamine effects, such as contraction of the smooth 
muscle but did not affect some others, like production of gastric acid, led the 
authors to the conclusion that the effects of histamine must be mediated 
by at least two different receptors. On the other hand, many of the so called 
antihistamines also inhibit muscarinic, α-adrenergic and serotonin receptors 
and modulate ion channels, which is reflected insuch as adverse effects such as 
dry mouth and other anticholinergic effects, orthostatic hypotension, increased 
appetite and arrhythmias, like torsades de pointes.
H1R is best known for its localization on the vascular endothelial and 
smooth muscle cells, whereas the best known localization of H2R is on the 
parietal cells of the stomach. High concentrations of histamine are already 
known to be responsible for vasodilation, increased vascular permeability, 
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the expression of adhesion molecules on vascular endothelial cells, 
contraction of the bronchial smooth muscle, stimulation of gastric acid 
production, neurotransmission in the central nervous system (CNS) and even 
modulation of immune-inflammatory responses via esosinophils, basophils, 
neutrophils/macrophages, MC, DC, T- and B-lymphocytes (Akdis & Blase 
2003; Simons 1999; Haas et al. 2008; Huang & Thurmond 2008 ; Feng et al. 
2013). Many of these already known histamine effects are rather acute and 
are apparently mediated by the classical H1R and H2R, where the requisite, 
high histamine concentrations are only achievable transiently following 
regulated, professional burst release. High-affinity H3R and H4R react to 
basal histamine concentrations, which are only 1/1000 – 1/10000 of the 
concentrations effectively activating H1R and H2R.
H1R mRNA is encoded by HRH1 gene in chromosome 3p25. The H1R protein is 
composed of 487 amino acids (de Backer et al. 1998). H1R is coupled via Gq/11 protein 
to activation of phospholipase C (PLC). This produces 1,4,5-inositoltrisphosphate 
(IP3) and 1,2-diacylglycerol (DAG), which cause calcium (Ca
2+) mobilization from 
intracellular stores and activation of Ca2+ and/or DAG-dependent protein kinase 
C molecules. H1R activation can also activate phospholipase A2 (which releases 
arachidonic acid from membrane phospholipids), phospholipase D (which 
releases phosphatidic acid from phospholipids) and transcription factor Nuclear 
Factor kappa K (NFκB) (Leurs et al. 2002). Some of the H1R on the cell surface 
membrane shows intrinsic (constitutive) activity without any histamine ligand 
binding, but the physiological consequences of this observation have not been 
clarified yet. Increased expression of H1R has been noticed in several diseases, 
such as allergic rhinitis, rheumatoid arthritis (RA) and in some areas of the brain 
as a result of stroke. 
Histamine promotes inflammatory responses and cytokines and some of 
these effects are mediated via H1R (Dy & Schneider 2004). H1R-antagonists, 
have shown effectiveness in the treatment of allergic rhinitis, conjunctivitis 
and skin reactions caused by exposure to allergens. CNS-related side effects, 
in particular sedation, have limited the use of the lipophilic first generation 
H1R-antagonists. More modern second generation H1R-antagonists are more 
hydrophilic molecules so their penetration through the blood-brain-barrier 
(BBB) and sedative effects are much smaller. Sedative side effects have been 
used in the treatment of allergic diseases associated with sleep disturbances. 
Cardiomyocytes express H1R and therefore H1R-antagonists could affect heart 
muscle and function, nevertheless no cardiotoxic effects have been described 
by the second generation H1R-antagonists (Simons 2004).
By and large, H1R activation seems to increase Ag presentation and 
costimulation to induce Th1/M1 type of immune responses, associated with 
e.g. IL-12 and IFN-γ production, at the same time when it is blocking humoral 
immunity and IgE production (Simons 2004).
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7.2.3.2. Histamine H2 Receptors
In the 1980s, the introduction of H2R-antagonists into the clinic revolutionized 
the treatment of gastric and duodenal ulcer and gastro-esophageal reflux 
disease (GERD). Because H2R-antagonists strongly inhibited the production of 
gastric acid (“no acid, no ulcer”), the earlier, mainly surgical treatments, like 
pyloroplasty or Billroth I or II type gastric resections, without or with vagotomy, 
were rapidly abandoned.  
The H2R is coded by HRH2 gene in 5q35.2 and the corresponding protein 
is composed of 359 amino acids (Traiffort et al. 1995) (Entrez Gene, HRH2). 
The H2R is coupled to Gαs-type G-protein. Binding of agonist to H2R stimulates 
adenylate cyclase, cAMP, protein kinase A (PKA) and cAMP response element-
binding protein (CREB), modifying both phosphorylation and more slowly 
gene transcription. Activation of H2R stimulates c-Fos, c-Jun (which together 
form the activating protein-1 (AP-1) transcription factor), protein kinase C and 
p70S6kinase (Dy & Schneider 2004; Jutel et al. 2009). 
H2R is found on parietal cells, but also on epithelial cells, endothelial cells, 
smooth muscles cells surrounding blood vessels, bronchiole, stomach and 
bowel, neurons, cardiomyocytes and cells of the immune system (neutrophils, 
eosinophils, monocyte/macrophages, DC, T- and B-lymphocytes). In the CNS, H2R 
is a postsynaptic receptor often occurring in the same locations as H1R, which 
may have synergistic effects between them (Haas et al. 2008). H2R knockout 
mice display impairment of cognitive functions and changed nociception. In 
contrast to H1R activation, H2R activation diminishes eosinophil and neutrophil 
chemotaxis (Simons 2004). H2R-agonism diminishes production of IL-12 
by monocyte-derived DCs (MoDC), where the cytokine polarizes Th0 to Th1 
cells, but this diminished IL-12 production can be prevented by H4R agonists 
(Gutzmer et al. 2005). Thus, H2R-activation seems to downregulate Th1/M1-type 
cell-mediated immuno-inflammatory responses and support Th2-inducing DCs 
and humoral immunity (Simons 2004).
Physiological effects mediated by H2R include relaxation of the smooth 
muscle layer of blood vessels, increased vascular permeability, increased 
production of mucus and bronchodilation, and positive chrono- and inotropic 
effects on the heart (Simons 2004). CNS-effects are uncommon, perhaps in part 
because H2R-antagonists are not lipophilic and do therefore not easily penetrate 
the BBB.
In 1975, Clark et al. discovered that low concentrations of histamine are 
chemotactic to eosinophils, whereas high histamine concentrations inhibit 
eosinophil chemotaxis, allowing them to participate in allergic inflammatory 
processes (Clark et al. 1975). After the discovery of H4R, which has a very 
high affinity for histamine, it has been shown that low, 10-100 nM histamine 
concentrations cause changes in the form of the cell, upregulation of adhesion 
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molecules (CD11b) and polymerization of the actin cytoskeleton via H4R 
(Buckland et al. 2003; Ling et al. 2004; Barnard et al. 2008). The low, nascent 
histamine concentrations that are generated and modulated by non-professional 
histamine synthesis have been shown to cause maturation of the secretory 
granules of MC, migration of MC and immunomodulation of DC, monocytes/
macrophages, Kuppfer cells and basophils (Ichikawa & Sugimoto 2010).
The high-affinity receptors can therefore be proposed to mediate the effects 
of low concentrations of histamine, such as far away from the acutely inflamed 
hot spots (or around it), where they can downregulate inflammation, at the same 
time as the histamine concentration gradient acts as a chemotactic stimulus 
attracting leukocytes to the site of ongoing inflammation. Perhaps even more 
importantly, the high-affinity receptors can be proposed to mediate important 
processes in between the histamine burst releases when influenced by the 
non-professionally produced, low nanomolar nascent histamine fluctuating 
concentrations or modulated by food-derived or microbially-produced 
histamine. It is not yet known how high micromolar histamine concentrations 
affect the highly sensitive histamine sensors H3R and H4R, which are already 
stimulated by nanomolar histamine concentrations and/or to a large extent 
spontaneously active.
Histamine can also bind to non-conventional proteins, such as some enzymes 
of the cytochrome P450 superfamily, histamine transporters and proteins 
secreted by some insects, like nitrophorins and lipocalins (Dy & Schneider 
2004). Lipocalins are highly specific histamine binding proteins, which are 
secreted by different types of ticks such as the hard tick (Ixodidae) and probably 
help the ticks to resist tick-bite-induced, locally-elicited host responses (Paesen 
et al. 1999). 
7.2.3.3. Histamine H3 Receptors
H3R (Lovenberg et al. 1999) is encoded by HRH3 gene in 20q13.33 (Tardivel-
Lacombe et al. 2001). H3R protein is composed of 445 amino acids, but over 
20 different isoforms are known (Cogé et al. 2001; Wellendorph et al. 2002; 
Wiedemann et al. 2002; Hancock et al. 2003), which suggests tissue, cell and 
context-dependent fine tuning in ligand binding and signal transduction.
One prominent H3R location is on the histaminergic neurons in the CNS 
and in peripheral nervous tissues. In the CNS, H3R acts as a presynaptic 
autoreceptor, where its activation inhibits neuronal histamine release (Haas 
et al. 2008; Passani & Blandina 2011). H3R also occurs as a presynaptic 
receptor on other non-histaminergic neurons, where they are referred to as 
a heteroreceptor. In these cells, H3R activation also inhibits the release of the 
corresponding neurotransmitters, such as acetylcholine, gamma-aminobutyric 
acid (GABA) and glutamate. All histaminergic CNS neurons, about 64,000 in 
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the human body, originate from the tuberomamillary nucleus, from which their 
axons pass to most other parts of the brain. Additionally, histamine released 
from the vagal complex of the nucleus tractus solitarii can probably modulate 
immune responses via H3R (Haas et al. 2008).
H3R is coupled to the Gi/o protein (Cogé et al. 2001; Bakker 2004; Leurs et 
al. 2005), which inhibits adenylate cyclase, but H3R activation can also activate 
mitogen-activated protein kinase (MAPK), increase intracellular calcium and 
activate phospholipase A2.
Histamine in the CNS is associated with regulation of the sleep-wake state, 
ability to concentrate, learning and memory as well as other phenomena. It has 
therefore been natural to assume that H3R-modulation could affect diseases 
which impair these functions, such as memory disorders in Alzheimer’s disease, 
narcolepsy and attention deficit/hyperactivity disorder (ADHD). Additional 
hopes have been raised of its potential in the treatment neuropsychiatric 
diseases, such as schizophrenia.
H3Rs are also found in the peripheral autonomic and somatosensory nerve 
terminals, which in turn can affect parasympathetic, sympathetic and sensory 
functions, such as pain and itch (4).
No drugs targeting mainly H3R are at clinical use yet, but effects of H3R 
inverse-agonists are studied in narcolepsy, sleep disturbances in Parkinson’s 
disease, ADHD, schizophrenia and Alzheimer’s disease as Phase II-III clinical 
studies (Passani & Blandina 2011). It is worthwhile to mention that betahistin, 
which is used in Ménière’s disease, is a weak H1R agonist, but a much more 
potent H3R inverse agonist. It was originally thought that H1R agonism relaxes 
pre-capillary sphincter muscles in small arterioles, thus improving the capillary 
circulation in cochlea (Ihler et al. 2012). Maybe the inverse agonist effect of H3R 
autoreceptors on neurotransmitter release and afferent sensory signaling in the 
vestibular nucleus and cochlea are more important in diminishing vertigo in 
Ménière’s disease (Desmadryl et al. 2012). 
7.2.3.4. Histamine H4 Receptors
H4R (Oda et al. 2000; Liu et al. 2001; Morse et al. 2001; Nguyen et al. 2001; Zhu 
et al. 2001; Nakamura et al. 2002) is encoded by HRH4 gene 18q11.2 (Cogé 
et al. 2001). The full length H4R is composed of 390 amino acids, but two non-
signaling receptor isoforms have been identified, H4(302 aa)R and H4(67 aa)R 
(van Rijn et al., 2008). Co-expression of these different isoforms may participate 
in downregulation of the full-length H4R on cell membrane, probably via receptor 
oligomerization. The amino acid sequence of H4R has a 37 % homology with 
that of H3R (58 % in the transmembrane region) (van Rijn et al. 2008). H4R is 
coupled to the pertussis-toxin sensitive inhibitory Gi/o protein (Gantner et al. 
2002). The identification of JNJ-7777120 and other potent and selective H4R 
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antagonists (Thurmond et al. 2008) made it possible to elucidate the roles of the 
H4R in a variety of allergic and inflammatory processes.
Intracellular signal transduction of Gi/o-coupled H4R occurs via inhibition of 
adenylate cyclase and lowered cAMP (Oda et al. 2000; Nakamura et al. 2000), 
increased phosphorylation of mitogen-activated protein kinase (MAPK) (Morse 
et al. 2001) and activation of PLC followed by increased cytosolic calcium and 
formation of DAG (Oda et al. 2000; Nguyen et al. 2001; Zhu et al. 2001). In a 
superficial way, the signal transduction cascades utilized by the novel H3R and 
H4R have resemblance, but this does not mean overlapping functions, because 
the cells and the cellular processes these receptors are coupled show wide 
variation. Due the common denominator of histamine for all histamine receptors 
known at present, combined with their generally prominent intrinsic activity, the 
system may maintain a rather complicated balance composed of interactions 
at the pre-, receptor- and post-receptor levels in cellular networks of various 
kinds (Nguyen et al. 2001; Xu et al. 2008; Hishinuma et al. 2010; Shi et al. 2012). 
This makes it difficult to extrapolate from simple in vitro experiments to human 
(patho)physiology.
H4R has a relatively high intrinsic constitutive activity. In spite of this half-
maximally active state, H4R reacts to histamine concentrations as low as 5-10 nM 
(Thurmond et al. 2008; Jablonowski et al. 2003; Akdis & Simons 2006). 
Expression of H4R has been well described in haematopoietic cells. Both 
myeloid and lymphoid cells express H4R, in particular eosinophils (Oda et al. 
2000; Buckland et al. 2003; Ling et al. 2004; Barnard et al. 2008), MC (Hofstra 
et al. 2003; Lippert et al. 2004), DC (Zhu et al. 2001; Damaj et al. 2007; Geng 
et al. 2012), Langerhans cells (LC, dendritic cells in the epithelium of the skin 
and mucosa) (Gschwandtner et al. 2010), CD4+ (Zhu et al. 2001; Sugata et al. 
2007; Gutzmer et al. 2009) and CD8+ T-cells (Zhu et al. 2001; Gantner et al. 
2002), CD16+ natural killer (NK) cells and CD1d-lipid complex binding invariant 
natural killer T-cells (iNKT) (Damaj et al. 2007; Leite-de-Moraes et al. 2009). H4R 
but not H3R is expressed on neutrophils (Oda et al. 2000; Zhu et al. 2001) and 
in experimental studies H4R-agonism seems to mobilize neutrophils from the 
bone marrow (Takeshita et al. 2003, Takeshita et al. 2004). On the other hand, 
H4R-agonism diminished monocyte-mediated production and secretion of CCL2 
chemokine, also known as monocyte chemotactic protein-1 (Dijkstra et al. 2007). 
Low H4R mRNA levels have been reported in B cells but the effects of receptor 
activation on B cells are not known yet (Zhu et al. 2001), although Breg chemotaxis 
and IL-10 and/or TGF-β production to alleviate arthritis (Mauri et al. 2003), 
systemic lupus eryhtematosus (SLE) (Lenert et al. 2005), inflammatory bowel 
disease (IBD) (Mizoguchi et al. 2002) and experimental allergic encephalopathy 
(EAE) (Mann et al. 2007) by these cells is one possibility.
Except for immune cells, H4R has been demonstrated thus far in skin 
fibroblasts and keratinocytes, fibroblast-like type B and macrophage-like 
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type A synovial lining cells and chondrocytes (Yamaura et al. 2013) as well 
as acinar and ductal epithelial cells in human salivary glands (Stegaev et al. 
2012). Low and somewhat inconsistent expression of H4R mRNA has been 
reported in osteoclasts, but no functional effects have been described 
(Biosse-Duplan et al. 2009). Expression of H4R in neuronal cells has been a 
matter of debate, but more recent studies report H4R in neurons of the nasal 
mucosa (Nakaya et al. 2004), primary vestibular neurons in rats (Desmadryl 
et al. 2012), neurons of the anterior horn of the spinal gray matter in mice 
(suggesting expression in motoneurons) (Lethbridge et al. 2010), in dorsal 
root ganglia in mice (suggesting expression in primary sensory neurons) 
(Kajihara et al. 2010), and in CNS in humans and rodents (Zhu et al. 2001; 
Connelly et al. 2009; Strakhova et al. 2009; Shan et al. 2012). H4R-agonist 
4-methylhistamine (4-MeHA) caused hyperpolarization of neurons of the 
somatosensory cortex in mice (Connelly et al. 2009). H4R, together with H1R 
and H3R, has been reported in dorsal root ganglion of skin-specific sensory 
neurons in mice (Rossbach et al. 2011). H4R stimulation led to an increase 
in cytosolic calcium. In experimental studies, H4R-antagonist has an anti-
pruritogenic effect, which could be due to a direct inhibition of the histamine-
sensitive free nerve terminals in the skin (Thurmond et al. 2008). H4R mRNA, 
again together with H1R and H3R mRNA, has been shown in human enteric 
neurons in the Meissner’s submucosal neural network, where neurons were 
excited by H4R stimulation (Breunig et al. 2007).
7.3. Histamine Transport
At physiological pH, histamine is a monocationic biogenic amine. Newly 
synthesized histamine is under homeostatic conditions released from the non-
professional histamine producing cells either via OCT2 and 3, also known as 
solute carriers SLC22A2 and SLC22A3 respectively or PMAT, also known as 
solute carrier SLC29A3 or equilibrative nucleoside transporter 3, (ENT3).
After burst release of histamine, both professional and non-professional 
cells have an outside-in histamine gradient. Both utilize OCT2/3 (SLC22A2/
SLC22A3) or PMAT (SLC29A3 or ENT3). PMAT transports other monoamines like 
serotonin and dopamine more effectively, with low affinity and high capacity. 
Equilibrative uniporters are not ATP-dependent active transporters, able to work 
against a concentration gradient, but let histamine and some other monovalent 
cations/biogenic amines pass along their concentration gradient. Histamine 
degranulation produces high histamine concentrations, perhaps up to 50 or 
even 100 μM. Part of the excessive histamine load is extracellularly degraded 
by diamineoxidase (DAO), which in general is considered to be responsible for 
15-30% of total histamine degradation. Locally released histamine is rapidly 
diluted by diffusion and carried away by body fluids.
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In cultured human HSG cells, 100 nM of radio-labelled histamine is enough 
to stimulate OCT3-mediated cellular uptake of histamine. On the other hand, 
after loading of these cells with 100 nM histamine, these cells release histamine 
from the cytoplasm to culture medium (Stegaev et al., 2013). This shows that 
OCT3 is functioning at rather low histamine concentrations, driven rather by the 
concentration gradient (and the negative resting cell membrane potential) than 
its high histamine affinity.
Extracellular de novo synthesized or dietary histamine can also be taken up 
by cells, which enables intracellular degradation (Duan & Wang 2010; Tanaka & 
Ichikawa 2011).
Both HDC isoforms are located on the endoplasmic reticulum, but only the 
53-kDa HDC localizes close to intracellular granules, probably to facilitate their 
storage of the newly synthesized histamine via vesicular monoamine transporter 
2 (VMAT-2) -mediated internalization (Tanaka & Ichikawa 2011). 
7.4. Histamine Degradation
After burst release of histamine from both professional and non-professional 
cells, a steep outside-in downhill histamine gradient is formed. Both cell types 
utilize then the aforementioned histamine channels for cellular uptake, but differ 
in their handling of intracellular histamine. In professional histamine producing 
cells, some of the intracellular histamine is subjected to granular re-uptake via 
VMAT2 for recirculation. Apart from histamine synthesis and release by host and 
commensal microbial cells, as well as the histamine content of food, histamine 
concentrations in the body are dependent on the mostly extracellular DAO-
mediated and intracellular HNMT-mediated histamine degradation processes 
mentioned above, which degrade histamine into imidazole acetate and 
N-methylhistamine, respectively. After cellular synthesis, DAO is initially located 
in vesicles located close to cell membranes, which upon stimulation release DAO 
into the extracellular space (Maintz & Novak 2007; Jutel et al. 2009). In mammals, 
DAO has been localized to the small intestine, ascending colon, placenta and 
kidneys. In renal tubular cells, DAO specifically localizes to the central clear matrix 
of the peroxisomes. Extracellular release of DAO and its activity in the extracellular 
space can be inhibited by various drugs, substances and alcohol. DAO-mediated 
extracellular degradation of histamine decreased in this way can increase 
histamine concentration and may cause histamine intolerance, depending on the 
individual and the context-dependent histamine response threshold (Maintz & 
Novak 2007). However, it is apparent that in the low nanomolar range levels of 
histamine concentration is continuously subjected to changes in the human body 
and sometimes peak to cause symptoms. In that respect, the basic non-professional 
histamine synthesis and intracellular degradation may exert important balancing 
(“buffering”) effects on the cellular histamine micromilieu. 
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7.5. Constitutive Receptor Activity
H4R has a high intrinsic constitutive activity meaning that it can exist in an active 
signaling state without a ligand bound to it. Normally ligand-free G protein-
coupled receptor is in an inactive R state and assumes an active R* conformation 
(R*) first after binding its specific ligand, but intrinsically active receptors have 
assumed a similar activated H4R* state in the absence of a receptor-bound 
ligand (Milligan et al. 1995; Leff 1995). The constitutive or basal H4R activity can 
therefore be described by the ratio between R* and R, and this basal activity is 
considered to be approximately 50% of the total H4R activity. In spite of this 
half-maximally active state H4R reacts already to histamine concentrations as 
low as 5-10 nM (Thurmond et al. 2008; Jablonowski et al. 2003; Akdis & Simons 
2006). This relatively high constitutive activity may suggest that there is a low 
and potentially harmful threshold value below which the cells cannot go without 
damage, and to avoid such deprivation of histamine effects, a quite large pool of 
the receptors is maintained in an active transducing state even in the absence 
of any ligands.
Another important consequence of the constitutive receptor activities is 
that various receptor ligands can act as agonists, neutral antagonists or inverse 
agonists. Binding of natural or synthetic agonists favour the active conformation 
and subsequent signal transduction. Binding of a neutral antagonist to the 
receptor does not favour active or inactive receptor conformation alone and 
therefore does not by itself affect constitutive signalling. However, a neutral 
antagonist competes with an agonist for receptor binding, and therefore 
inhibits agonist-mediated receptor activation and signal transduction. Binding 
of inverse agonists (which earlier were also called antagonists) stabilizes and 
thus promotes the inactive receptor conformation, which leads to a shift of 
spontaneously active receptors to the inactive receptor pool and thus inhibits 
the constitutive receptor activity. This way, an inverse agonist diminishes the 
spontaneous receptor activity below the regular constitutive signalling level. 
All four histamine receptors have been shown to be generally constitutively 
active, but this is probably particularly important for H3R and H4R (Smit et al. 
1995; Bakker et al. 2000; Morisset et al. 2000; Oda et al. 2000)., However, 
the importance of the balance between the H1R-H4R constitutive signalling 
pathways and the “off-state” and “on-state” function of various cells remains an 
interesting but open question.
7.6. Recognized Histamine-associated Diseases
Most known histamine-associated diseases in man seem to relate to enforced 
expulsion of micro- and macrostructures from the human body, such as pollen 
(~10-1000 μm) or parasitic worms (largest of which is broad tapeworm, which 
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grow usually 5-6 meters long, being then almost as long as the average human 
small intestine)(Pulendran & Artis, 2012). Pollen, eggs or larvae can intrude the 
human body via air (pollen via conjunctivae, nasal mucosa, airways), by mouth to 
the bowel and other internal organs (eggs ot tape worms etc.) or through the skin 
from where they can also reach the bowel and other internal organs (e.g. larvae 
in schistosomiasis). Many times they can be expelled, in part via burst released 
histamine triggered by lectin-like, MC activating structures (Imamura et al. 
1996; Pramod et al. 2007), which is followed by tearing, sneezing, coughing 
or expulsion from the bowel. If the condition develops further, these reactions 
develop, like wound healing, to a robust type 2 rather than type 1 immune 
responses. This engages DC2, Th2 and M2 but for the initation of the type 2 
response innate MCs and basophils and their cytokines such as IL-5 and IL-13 
(later produced by Th2 cells together with IL-4) play important roles (Gordon 
2003). Parasites participate actively in the induction of the host response by 
producing excretory/secretory products (proteinases, chitins) and egg Ag, 
which via danger receptors and T- and B cells receptors (TCR/BCR) interact 
with DC2, MCs, basophils, eosinophils, goblet cells, enterocytes, M2, Th2 and 
B cells (Wilson et al., 2007). In more chronic stages, the intruder can in part 
be isolated to granulomas, fibrosis and calcified cysts. One promising strategy 
in the treatment of these diseases is vaccination aiming to strengthen type 1 
responses or immunotherapy aiming to induce Treg and suppression/tolerance, 
in which H4R may plays a role.
Before the host response caused by direct irritation and naïve inflammatory 
responses e.g. of the airways, such as sneezing or coughing, can be strengthened 
by IgE-enhanced, MC- and basophil-mediated immediate-type I immune 
responses, the body must be sensitized. This engages DC-T-cell interactions, 
which are in part regulated by nanomolar histamine and H3R and H4R. If the 
body in spite of the initial non-immunological, irritative and naïve “get rid of the 
intruder”-type host responses cannot get rid of the intruder, its components are 
taken up and apart by the professional Ag-processing and -presenting DCs. Foreign 
Ag (linearized epitopes) are then in secondary lymphatic tissues presented in 
the context of major histocompatibility complex class II (MHC II) to TCR. For 
the T-cell to be activated by this Ag presentation, it needs also costimulatory 
signals, which are produced as a response to exogenous or endogenous (tissue 
damage) danger signals. Also B-cells present these Ag in the context of their 
surface MHC II to T-cells. If the Ag presenting B-cell recognizes an epitope of the 
same Ag in its soluble form by its surface immunoglobulin (viz. BCR, which was 
used to internalize the Ag in the first place), it becomes a plasma cell producing 
soluble antibodies. This is a joint result of the T-cell help, which provides co-
stimulatory signals for the B-cell activation, and the Ag presentation to the B-cell 
via BCRs. In type 2 IL-4 and IL-13 driven response the immunoglobulin isotype 
switches from surface IgM and surface IgD to soluble IgE or IgG4. This might in 
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part be related to the route of entrance of the irritatant immunological stimulus 
and its character. Sensitization and production of IgE help to expel the irritant 
even more effectively because the weaker and direct host responses are now 
enforced by an effective immunological activation of MCs and basophils. If this 
IgE production is local and the exposure only temporary, it could serve a useful 
purpose. However, if the IgE production is excessive, IgE spreads to more distant 
sites and the condition transforms to a disease-like and disturbing state known 
as allergy. 
Thus, DC-lymphocyte interactions, sensitization and delayed T-cell-dependent 
immunological reactions related to H3R and H4R preceed the development of 
immediate, allergic repellent host responses related to H1R and H2R. It has long 
been known that this sequence is nicely depicted in reactions to mosquito bites 
(Mellanby 1946). Non-exposed and non-sensitized individuals do not produce 
any macroscopic skin response (stage I). After a number of mosquito bites the 
Ag dose is enough to lead to a delayed response apparent after one to several 
days after the bite (stage II). If the exposure to mosquito bites continues, an 
immediate response starts to develop to the bite in some 15 minutes and 
remains symptomatic for 1-2 hours (stage III). If the exposure to the salivary 
proteins released by the mosquito during its blood meal continues, the delayed-
type response disappears and only the immediate-type response continues 
(stage IV); possibly as a result of development of inducible regulatory T-cells 
(iTreg) and blocking IgG4. No more IgE antibodies are produced but some IgE still 
passively maintains the immediate type I reaction mode, a similar phenomenon 
as is seen in the Prausnitz-Küstner test. Upon further exposure, Ag-specific IgE 
diminishes and this leads to complete tolerance (stage V) so that in Lapps (Sami 
people) mosquito bites do not cause any response at all.
7.7. Immune Defence and Autoimmune Diseases
Self-tolerance fails severely in autoimmune diseases, which leads to cell and 
tissue pathology, patient symptoms and other clinical signs and findings (“horror 
autotoxicus”).
According the clonal selection theory of immunity, central tolerance of 
the bone marrow-derived CD4-, CD8- and TCR- progenitor cells is established 
during their differentiation in the thymus. In cortical thymus, T-cell receptor 
gene rearrangement occurs followed by positive selection (clonal amplification) 
of properly finely-tuned lymphocytes, showing moderate self (MHC I or II) 
reactivity. T-cells showing overly weak reactivity against self-MHC molecules are 
subjected to negative selection via death by neglect, as they respond too weakly 
for their function even to Ag-loaded MHC complexes. Similarly, T-cells reacting 
too strongly against self-MHC antigens undergo activation-induced apoptosis, 
because they would be able to cause rejection of autologous tissue. 
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From the cortical thymus, CD4+, CD8+ double-positive T-cells pass to the 
thymic medulla, where they are now confronted with various self-Ag loaded to 
MHC, produced ectopically in situ as a result of molecules like AIRE (autoimmune 
regulator): very weakly reactive T cell clones die out of neglect, weakly self-reactive 
T cell clones can become conventional effector T cells (Teff), moderately self-reactive 
and costimulated T cell clones with a quite wide TCR diversity become stable 
natural regulatory T cells (nTreg; CD4
+, CD25+, Foxp3+ nTreg) and strongly self-reactive 
T cell clones undergo activation induced apoptosis. Roughly 5% of the total T-cells 
subjected to clonal selection are then released as naïve T cells into the periphery. 
What is often forgotten is that the thymus undergoes involution after its peak 
development in puberty. Body is then largely dependent on the 108 T naïve cell 
clones produced, each clone consisting of 1000-10000 cells, depending on whether 
the total number of T cells is estimated to 1011 or 1012 (Arstila et al. 1999; Arstila 
et al. 2000). Interestingly, most of these T-cells never meet their specific antigenic 
determinant, as memory T-cells only make up < 1 % of the total cell diversity.
Due to various harmful events, such as trauma leading to a release of potential 
auto-Ag, it is also necessary to establish peripheral tolerance. This seems to be 
in part based on the danger signals. In the absence of danger signal-induced 
costimulatory factors, presentation of Ag alone leads to apoptosis of the 
lymphocyte (dying away), anergy of the lymphocyte (weaning away) or formation 
of CD4+, FoxP3+ inducible regulatory T cells (iTreg, active resistance), preferably in 
the presence of a low dose of a high affinity antigenic determinant together with 
CD28 co-stimulation. iTreg cells are important for example for tolerance against 
food Ag and commensal flora, where the development of these populations 
require a suitable cytokine milieu, in particular TGF-β (Yuan et al. 2012).
Anti-idiotypic responses also provide a means to control immune activation. 
All TCR and BCR contain highly variable but always clone-specificidiotopes, 
which are the structures responsible for the binding of epitopes (antigenic 
determinants). An oligoclonal, Ag-driven response defines a set of idiotopes, 
which is collectively referred to as an idiotype. For down-regulation of the 
immune response, anti-idiotypic TCRs and antibodies, representing “internal 
images” of the Ag, are produced. They bind to the antigen-specific TCR and BCR 
and can block Ag binding and responses. However, anti-idiotypic antibodies are 
not always restricted to blocking, as histamine burst release stimulating anti-
idiotypic antibodies against IgE have been reported (Boutin et al. 1993).
The peripheral tolerance presented above is reactive, but it is also possible 
that some degree of proreactive autoimmunity is necessary for the maintenance 
of the immune balance. Self reactive lymphocyte clones could be maintained 
for active surveillance to recognize and respond to biomarkers, which reveal the 
site of the offence through tissue specific Ag, the type of the offence (cytokines, 
tissue damage induced inflammation, etc.) and the stress associated with it 
(stress proteins and the condition of the local cells) (Cohen 2007).
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Because central selection is not 100% effective, autoimmunity could 
be based on molecular mimicry between microbial and self-Ag. Even in the 
absence of any initial cross-reactivity, a persistent infection can lead to epitope 
spreading, which reaches a point in the Ag where self-mimicking, cross-reactive 
epitope scripts are met. Professor Shunichi Shiozawa has introduced a model 
in which a persistent release of self-Ag even in the absence of infection (as 
a result of auto-Ag release upon exposure to UV light in SLE, for example) 
overstimulates the immune system so the self-organized criticality limit is 
surpassed, causing immune receptors to undergo de novo revisions leading 
to new reactivities which cover self-Ag (Tsumiyama et al. 2009). In bystander 
activation the antimicrobial response occurs in an infected and damaged 
tissue containing self-Ag in an environment invaded by mature and competent 
antigen presenting cells (APC) in a cytokine milieu favoring expression of co-
stimulatory molecules. This leads to an immune attack against an innocent 
bystander self-Ag. Self-tolerance can be maintained by apoptosis which 
produces dominant tolerogenic antigenic determinants that only stimulate 
synthesis of anti-inflammatory cytokines. If this normal Ag processing is 
diverted as a result of tissue pathology, the very same Ag can instead produce 
hidden (cryptic) immunogenic epitopes, creating new self-derived molecules 
which lymphocytes did not meet during its education, eliciting an immune 
response.
7.8. Mast Cells and Autoimmunity
MCs are derived from the hematopoietic stem cells of the bone marrow, 
their precursors circulate in blood and they differentiate into granule-loaded 
“explosive” mature MCs in different tissues (Abraham & St. John 2010). In 
human tissues, tryptase-negative precursors or proliferation of MCs seem to 
be rare (Čeponis et al. 1998). Some tissue specificity in the final maturation is 
suggested by the dichotomy of MCs in rodents to mucosal MCs positive for mast 
cell tryptase and connective tissue MCs also positive for mast cell chymase. In 
contrast to murine MCs, human MCs do not produce IL-4 or express CD14 and 
IL-3R, FcγRI or functional TLR receptors are expressed in very small amounts, but 
they are strong IL-5 producers (Bischoff 2007). IL-5 stimulates B cell proliferation, 
increases immunoglobulin secretion and activates eosinophils.
MCs are best known for their role in immediate type I hypersensitivity 
reactions. IgE molecules with specificity against allergens like pollen) bind to MC 
surface FcεRI. When these sensitized MCs encounter allergens, cross-linking of 
the cell surface-bound IgE molecules leads to MC degranulation and activation. 
MCs can be stabilized by the drug sodium cromoglycate but also naturally by 
inducible OX40 on the surface of activated iTreg cells, which interacts with OX40L 
on the MC surface (Mekori & Hershko 2012).
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MCs contain also other preformed granular mediators like mast cell tryptase, 
heparin, IL-5, GM-CSF (granulocyte-monocyte colony stimulating factor), TNF-α, 
IL-17A and IL-17C. These cells can synthesize various eicosanoids as well as 
chemo- and cytokines. In a MC-dependent mouse model of zymosan-induced 
peritonitis, an H4R-antagonist blocked neutrophil infiltration (Thurmond 
et al. 2004). Due to their role in DC maturation, polarization, migration, Ag 
presentation and other immunomodulatory processes, MCs participate in 
many autoimmune diseases, such as multiple sclerosis, bullous pemphigoid 
and RA, as demonstrated by lack of arthritis in MC-deficient mouse model and 
in RA by the improvement of type c-kit tyrosine kinase inhibitors (Eklund & 
Joensuu 2003). 
MCs can produce IL-12 and IFN-γ, which can polarize D0, M0 and Th0 cells to 
type 1 cells; human MCs contain IL-5, both preformed and de novo produced, 
which can contribute to the polarization of other cells to type 2 cells; IL-6 and 
TGF-α, which can polarize cells to type 17 cells; and finally TGF- and IL-10, which 
can help polarize cells to Treg. The outcome of the process to a large extent is 
context dependent. In particular, histamine decreased the production of poly 
I:C-induced, type 1 polarizing IL-12 by monocyte-derived DCs upon H4R-agonist 
pretreatment (Gutzmer et al. 2005). Histamine at high concentrations also 
diminished lipypolysaccharide (LPS)-induced IL-12 production and promoted 
type 2 polarisation of DC and Th0 cells via H1R and H2R (Caron et al. 2001; 
Kitawaki et al. 2006). MC can even present Ag to CD4+ T-cells (Fox et al. 1994) 
and cross-present Ag to CD8+ T-cells (Stelekati et al. 2009).
7.9. Dendritic Cells and Autoimmunity
H4R mediates chemotaxis of human human myeloid DCs (Gutzmer et al. 2005). 
DCs are professional cells responsible for Ag sampling and surveillance. They 
capture (for which the outspread dendritic morphology is very suitable), 
transport (often through losing the dendritic morphology) and proteolytically 
process Ags and present it to T-cells after induced maturation, such as by danger 
signals, certain cytokines and immune complexes. DCs are often referred to 
as professional APCs, due to their critical role in primary immunization and 
sensitization, as no other cells are able to activate naïve T-cells (Steinman & 
Banchereau 2007). This functionality may depend on their capacity to migrate to 
secondary lymphoid tissue where they effectively interact with densily packed 
T-cells as interdigitating DCs in the paracortical T-cell area. 
Ag presentation by DCs can result in induction of tolerance or immune 
activation. The two main categories of human DCs are conventional or myeloid 
CD11c+, CD123- DCs (cDC or mDC, which can express TLR1-6 and TLR8) and 
plasmacytoid CD11c-, CD123+ DCs (pDC, naïve interferon type I-producing cells, 
characterized by TLR7 and TLR9) (Hashizume et al. 2005). CD11c is an integrin 
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αx subunit, part of the Int αxβ2 complement receptor 4 for inactivated-C3b (iC3b), 
whereas CD123 is interleukin-3 receptor (IL-3R).
CD11+ DC may have several subsets: CD16+ DCs in blood, CD1c+ (BDCA-1+), 
which strongly expresses TLR4 and produces IL-10 and IDO in response to whole 
E. coli (Kassianos et al. 2012) and CD141+ (BDCA-3), which strongly expresses 
TLR3 and effectively induces Th1 responses (Jongbloed et al. 2010).
DCs can also be classified as immature and mature, migratory (collecting Ags 
in the periphery as peripheral sentinels then migrating along lymphatic vessels 
to secondary lymphatic tissues to present them) and resident (possibly arising 
from blood-borne precursors or formed in situ in one lymphoid organ, where 
antigens are collected and presented in the organ before the cells undergo 
apoptosis) as well as non-polarized (DC0) or polarized, where the latter is 
comprised of DC1, which are produced by contact with stimuli such as bacteria 
including mycobacteria or poly I:C and induce a Th0-to-Th1 shift by producing 
IL-12 and DC2, which are produced by contact with stimuli such as helminths, 
thymic stromal lymphopoietin (also produced in epithelia) and PGE2 and induce 
a Th0-to-Th2 shift by producing IL-4 and other Th2 polarizing cytokines.
Both immature and mature DCs express H1R, H2R, H3R and H4R (Gutzmer et 
al. 2005; Jutel et al. 2009). DCs produced from human monocytes with GM-CSF 
and IL-4 belong to the non-professional histamine producing cells containing 
HDC and histamine, both of which increase up to 300-400% upon culture up to 
day 5. HDC inhibition as well as H1R-antagonists and H2R-antagonists decrease 
the DC differentiation-associated CD45 expression from day 3 by 60-80 % 
of control values. DPPE, inhibits histamine binding to microsomal and nuclear 
structures and downregulates CD40, CD86, CD33, HLA-DR and CD11c (Szeber 
nyi et al. 2001). Higher histamine concentrations achieved via MC degranulation 
exceed previously established peripheral tolerance via loss of Treg suppression 
and lead to T-cell-mediated acute rejection of the skin graft (de Vries et al. 
2009). However, this may relate to deprivation of tryptophan, another important 
MC product (Nowak et al. 2012).
Further support for the role of H4R in the maturation of DCs, possibly via H4R-
agonism, has been obtained in asthma models. HDC knockout mice maintained 
on a histamine-free diet had reduced OVA-sensitized and challenged airway 
hyperreactivity, BALF eosinophilia, OVA allergen-specific IgE and late phase 
cytokine levels (Kozma et al. 2003). The questions are how much histamine 
was in these mice produced by the intestinal microbial flora and how important 
a role the constitutive activity of H4R plays in this model. Histamine-binding 
tick protein given before OVA-Ag challenge effectively prevented murine OVA-
induced allergic asthma associated bronchial hyperreactivity, peribronchial 
inflammation, pulmonary eosinophilia, mucus production and IL-4 and IL-5 
secretion (Couillin et al. 2004). These histamine effects may be mediated via H4R 
because H4R knockout and H4R-antagonist treated mice have decreased lung 
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inflammation and Th2 responses (Dunford et al. 2006). H4R-agonism favours 
DC2/Th2 responses, whereas lack of histamine and H4R-antagonism diminish 
Th2 responses.
CD1a+, CD207+ (Langerin, a C-type lectin, which is a crucial component of 
Birbeck granules) Langerhans cells (LC) are perhaps the best known DC, residing 
in the epithelia of skin and mucosa LCs are monocyte/macrophage-derived DCs 
but seem to replenish to a large extent by local self-renewal. They belong to the 
so-called migratory DCs and can capture Ag by macropinocytosis, phagocytosis 
or receptor-mediated endocytosis after a local insult, leading to production 
of LC mobilizing TNF-α and IL-1β and then transport it to local lymph nodes. 
Once localized, LCs seem to participate in the maintenance of self-tolerance via 
activation, clonal proliferation and the maturation of iTreg (Idoyaga et al. 2013). 
Interestingly, naïve T-cells seem to enter lymph nodes via high endothelial 
venules (HEV), whereas memory/effector T-cells enter mainly via afferent 
lymphatics (Förster et al. 2012).
Dermal cDCs residing in the upper dermis are composed of two subtypes: 
CD1ahigh, CD14-, CD206high and CD1alow, CD14+, CD206low, CD209 (DC-SIGN) 
subsets, both of which express the coagulation factor XIII (Toebak et al. 2009; 
Chu et al. 2011). A special subtype of DCs, inflammatory dendritic epidermal 
cells (IDECs) are equipped with low- and high-affinity FcεRs (type II and I) and 
occur in skin lesions in atopic dermatitis. Cross-lining of the high affinity FcεRI 
IgE-receptor leads to IL-12 and IL-18 release, and Th1 polarisation. Th2-mediated 
inflammation with IL-4, IL-5 and IL-13 as well as IgE-driven MC degranulation 
prevail during the acute phase of atopic dermatitis, whereas eosinophils, 
macrophages and Th1 response with IFN-γ production are characteristic for 
the chronic phase with thickening of the epidermis and dermal fibrosis. IFN-γ 
increased H4R on human monocyte-derived IDEC (Dijkstra et al. 2008).
Histamine can via H2R stimulate endocytosis of Ag (Amaral et al. 2007). 
Regarding resident murine spleen DCs, histamine decreases their Ag 
presentation capacity in an apparently H4R-mediated manner, as this effect was 
inhibited by a H4R-antagonist and enhanced antigen presentation was observed 
in H4R-/- DCs (Simon et al. 2011). After uptake of Ag, DCs can also pass them 
from the endocytotic compartment to the cell cytoplasm to be processed by the 
proteasome for cross-presentation of the antigenic epitopes in the context of 
MHC I. Cross-presentation is necessary for the mobilization of CD8+ killer T-cells 
against malignant and virally infected cells if the DC themselves are not affected 
and would thus not be able to present tumour or viral Ags. Via H3R and H4R, 
histamine at low concentrations can stimulate cross-presentation of soluble but 
not particulate endocytosed Ags (Amaral et al. 2007). MHC I-restricted cross-
presentation of self-Ag leads to induction of tolerance through deletion of 
autoreactive CD8+ T-cells (Kurts et al. 1997). Therefore, it is possible that H4R 
stimulation maintains production of tolerogenic DCs (tol-DC) during a steady 
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low histamine state, whereas adaptive immunity is raised against infections, 
which trigger DC-mediated production of IL-12 and IFN-α (Steinman et al. 
2003). Activated DCs can rapidly recruit cells with a capacity to produce more 
cytokines, namely NK cells, which express H4R (Damaj et al. 2007), and iNKT, in 
which H4R is required to IL-4 and IFN-γ synthesis (Leite-de-Moraes et al. 2009).
DCs regulate the polarization of naïve CD4+ Th0 T-cells, which can be polarized 
to Th1 effector cells via IFN-γ and IL-12, producing IFN-γ, GM-CSF, CCR5 and 
CXCR3, to Th2 effector cells via IL-4, producing IL-4, IL-5, IL-13, CCR3 and CCR4, 
to Th17 effector cells via IL-6 and TGF-β, producing IL-6, IL-17, IL-22, CCR6 and 
IL23R, to TFH cells via IL-6 and IL-27, together with interactions with follicular B 
cells or to iTreg cells via IL-10 and TGF-β, producing IL-10, TGF-β and IL2R (Steinman 
& Banchereau 2007). Th1 and Th2 cells predominantly (but not exclusively) 
express H1R and H2R, respectively. H4R deficient mice and mice treated with H4R 
antagonist had decreased OVA-induced allergic lung inflammation and ex vivo 
induced T-cell-mediated IL-4, IL-5 and IL-13 production (Dunford et al. 2006). 
H4R expression has been shown on Th1, Th2 and Th17 cells (Mommert et 
al. 2011). Stimulation of H4R on Th17 cells increased production of IL-17A and 
intracellular activation of activating protein-1 (AP-1) (Mommert et al. 2012). Th17 
cells have been shown in psoriatic skin lesions and in acute atopic dermatitis. 
H4R-agonists stimulate Th2 cells to produce IL-31, which causes itch (Mommert 
et al. 2011). This suggest that H4R plays a role in the modulation of T-cells, which 
participate in the pathomechanisms of inflammatory skin diseases. Although 
we still lack detailed mechanistic studies, iNKT-cells have been associated with 
autoimmune diseases like primary biliary cirrhosis (PBC), psoriasis, MS, SS, SLE 
and RA (Simoni et al. 2013). In experimental PBC model, iNKT-cells play a key 
role in the initiation of the disease whereas iNKT-cells in other autoimmune 
diseases are supposed to play a stronger role during the chronic stages. These 
disease-promoting effects can depend on inappropriate activation of iNKT-cells 
(such as in psoriasis) but also on defects in their immunoregulatory functions 
(such as MS, RA).
7.10. Regulatory T-cells and Autoimmunity
There are two main types of regulatory T cells. Naturally occurring nTreg are 
centrally-produced in thymus from naïve T-cells (Tn) by exposure to IL-2, TGF-β 
and Ag and include CD4+, CD25+ and Foxp3+. Adaptive iTreg are produced in the 
periphery in lymphocyte tissue via tolerogenic mechanisms by exposure of Tn to 
IL-2, TGF-β and Ag presented by tol-DC. 
Differentiation of DCs to tol-DCs upon exposure to IL-10 and TGF-β (or 
corticosteroids) starts by expression of tolerogenic immunoglobulin-like 
transcripts (ILT3 and ILT4) at the same time when costimulatory molecules (CD40, 
CD80, CD86 and IL-12) and MHC II are down-regulated. Tol-DCs produce IL-10 
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and TGF-β upon Ag presentation in mucosal surfaces and induce Th0 cells to iTreg 
which cause oral tolerance. Production of indoleamine 2,3-dioxygenase (IDO) 
by tol-DC contributes to immunotolerance. H3R/H4R-agonist enhance cross-
presentation and tolerance by deletion of autoreactive CD8+ cells, whereas 
the presence of danger signals, such as TLR-ligands and GM-CSF, would favor 
formation of CD8+ effector T cells.
In humans, Foxp3 is not restricted to iTreg, which can be recognized as CD127
lo, 
CD25+ and CD4+ cells. IL-10-produces inducible type 1 regulatory T cells (Tr1 Treg 
and TGF-β- Th3 Treg, which both are Foxp3
-. Regulatory T cells in general down-
regulate immune activation by producing IL-10, TGF-β and IL-35 (Burrell et al. 
2012), by expressing immunosuppressive surface molecules, such as CTLA-4, 
and by inducing production of IDO in APC. H4R-agonists are chemotactic to Treg 
and can stimulate IL-10 production (Morgan et al. 2007).
Regulatory B10 cells are produced when B10-cell precursor via BCR is 
stimulated by an auto-Ag. Auto-Ag is internalized and its determinants are 
presented in a B-cell surface MHC II to TCR, whereas a B-cell surface CD40 
stimulates the T-cell via CD154. This induces T-cell produces interleukin-21, 
which via B-cell surface IL-21R stimulates the matured B10 cell to produce IL-10 
to down-regulate T-cell function. 
7.11. Atopic Dermatitis and Inflammatory Skin Diseases
The natural history of atopic manifestations (“allergic march”) is characterized 
by a sequence of atopic dermatitis and food allergy (peak prevalence at the age 
of 1 year), followed by asthma (peak prevalence at the age of 5-8 years) and 
finally allergic rhinitis (and conjunctivitis) reaching a peak plateau at the age 
of 12 years. Increased lesional histamine concentrations have been described 
in prick-tests, urticaria, allergic contact dermatitis and psoriasis (Thurmond et 
al. 2008; Gutzmer et al. 2011), but in spite of some older suggestive studies, 
the situation is not clear in atopic dermatitis (Ständer & Steinhoff 2002). In 
a dog model for atopic dermatitis, histamine increased only locally for 1-3 
hours after challenge (Bäumer et al. 2011). H1R-antagonists have incomplete 
effects and it has therefore been suggested that maybe H4R modulation could 
be helpful here. H4R has been shown in keratinocytes, dermal fibroblasts, MCs, 
eosinophils, dermal DCs, LCs and nerve cells in the skin, but this depends on 
the differentiation, localization and external stimuli (Damaj et al. 2007; Dijkstra 
et al. 2008; Ikawa et al. 2008; Gschwandtner et al. 2010). H4R is higher in the 
upper than in the lower epidermis (Yamaura et al. 2009) and stimulation with 
LPS, indomethacin and dexamethasone increases H4R mRNA and/or protein in 
dermal fibroblasts. 
Atopic dermatitis is characterized by increased numbers of MCs in skin lesions 
and often dietary or pollen allergies. Increased serum IgE values (Liu et al. 2011) 
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correlate positively with the disease activity and treatment with anti-IgE (e.g. 
omalizumab) is occasionally effective. IDEC are characteristic for atopic eczema 
and disappear upon successful treatment (Wollenberg et al. 1996; Wollenberg 
et al. 2001). Acute atopic dermatitis is characterized by a Th2 response (IL-
4, IL-5, IL-13) but a chronic disease by Th1 milieu (IFN-γ) and lichenification, 
epidermal hyperplasia and dermal fibrosis caused by scratching (Dijkstra et 
al. 2008; Simon et al. 2004). Dermal eosinophil infiltrates are prominent and 
eosinophilic cationic protein ECP can be used to evaluate disease activity.
Three different single nucleotide polymorphisms (snp) have been described 
in HRH4 gene coding H4R in atopic dermatitis, suggesting that this receptor may 
play a role (Yu et al. 2010). MC and eosinophil H4R may mediate chemotaxis. 
IDEC is H4R positive and stimulation of H4R (but not modulation of the other 
histamine receptors) of IDEC led to diminished production of Th2-chemokine 
CCL2 (attracting monocytes, activated T-cells and NK-cells) and Th1-polarizing 
cytokine IL-12 (Dijkstra et al. 2008), suggesting that low level histamine, if 
maintained, may down-regulate the immune-inflammatory activity of these 
cells.
LCs in atopic dermatitis can probably act as pro-inflammatory, 
immunosuppressive or tolerogenic cells. LCs express functional H4R which by 
low histamine concentrations or by specific H4R-agonists down-regulates CCL2 
production. This also increases their migration ex vivo from the skin, normally 
indicating migration towards secondary lymphatic organs (Gschwandtner et al. 
2010; Chu et al. 2011).
Th1, Th2 and Th17 cells are immunological effector cells in human inflammatory 
skin diseases and they can all express H4R (Mommert et al. 2011), which is in vitro 
upregulated by the Th2 cytokine IL-4. H4R stimulation increases production of 
pruritogenic IL-31 (Gutzmer et al. 2009), in particular in atopic dermatitis.
Also chronic idiopathic urticaria is associated with increased MC numbers, 
in which disease IgG auto-Ab against the FcεRI can trigger MC degranulation. 
MCs in skin express mostly H2R and H4R (Lippert et al. 2004). In a FITC-induced 
Th2-driven inflammatory contact dermatitis in mice H4R-antagonists had anti-
inflammatory effects (Cowden et al. 2010b), perhaps via DC by diminishing their 
mobilization from skin to lymph nodes and thus Th2 polarization. Symptomatic 
effects were not seen in MC-KO mice suggesting that here H4R-antagonists acted 
directly on MCs. Similar results, combined with diminished serum IgE levels, 
were obtained in a TNCB-driven mouse model with H4R antagonists started 
before sensitization and continued during TNCB-treatment (Suwa et al. 2011). 
In contrast, in an acute dog (Bäumer et al. 2011) and mouse (Seike et al. 2010) 
models H4R-antagonists were not helpful. 
Recently, dual inhibition of H1R/H4R has been advocated (Matsushita et 
al. 2012; Ohsawa et al. 2012). Monotherapy with H4R-antagonist diminished 
IL-4, IL-5 and IL-6, but increased IL-12 and IFN-γ. Increase of IL-12 and IFN-γ 
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was not seen in animals treated with dual inhibition. Dual inhibition helped 
against itch and was as effective in the overall treatment as prednisolone for 
which it might offer an alternative in the future. In contrast to H1R-antagonist, 
H4R-antagonist had an effect both on histamine and substance P induced 
itch (Yamaura et al. 2009), which may be mediated directly via H4R
+ sensory 
nerves (Dunford et al. 2007), where H3R inverse agonist caused dose-related 
itch which was totally blocked by a combined treatment with H1R- and H4R-
antagonists (Rossbach et al. 2011). Therefore, it was concluded H1R and H4R 
stimulation and H3R-inverse agonist all cause itch (and calcium increase in 
the neuronal cells). 
7.12. Asthma
Asthma is a chronic, inflammatory and often immune-based disease that mostly 
targets the small contractile bronchioles of the airways, characterized by a 
smooth muscle wall and eosinophil, MC and T-cell infiltrates (Bousquet et al. 
2000). Dyspnea, cough and wheezing are typical symptoms. These features are 
inducible by H1R-agonists, but in spite of this H1R-antagonists are not effective 
in the treatment of asthma (Thurmond et al. 2008). Asthma may be extrinsic 
(atopic, with type 1 hypersensitivity to allergens) and intrinsic (non-atopic) and 
both Th2 lymphocytes/IgE/MC and innate helper type 2(Ih2)/IL-5/eosinophils 
play important roles in it. 
Chemokines and cytokines are not only produced by the rapidly acting MCs, 
basophils and eosinophils, but also by DC, macrophages and in particular T- 
and B-cells, which are readily present in newly-diagnosed asthma (Laitinen et 
al. 1993). In untreated and newly diagnosed airway epithelium (BALF may not 
accurately reflect tissue events), 612 lymphocytes (110 in controls, p<0.05), 
120 MCs (7 in controls, p<0.001), 75 eosinophils (0 in controls, p<0.05), and 
15 macrophages (0 in controls, p < 0.05) per mm2  were counted (Laitinen et 
al. 1993). The situation was possibly further lymphocyte-dominated in airway 
lamina propria, where the lymphocyte values were 656 vs. 155 (p<0.001), 
plasma cells were 285 vs. 27 (p<0.001), macrophages were 44 vs. 3 (p<0.001) 
and monocytes were 11 vs. 1 (NS), whereas the MCs were 124 vs. 88 (NS) and 
eosinophils were 134 vs. 3 (p<0.001). These findings suggest that asthma may 
basically be a lymphocyte-based immunological disease.
As demonstrated by the cellular pathology above, asthma and other atopic 
diseases can be divided to two different phases, the sensitization phase and 
the challenge phase (Little et al. 2003). In the sensitization phase, the mucosal 
membrane and mucosal-associated lymphatic tissue (MALT)) are exposed to a 
potential aeroallergen (Bielory et al. 2013), leading to IgE production in type 2 
response in pulmonary hilar lymph nodes with involvement of DCs, CD4+ T-cells, 
CD8+ T-cells, B-cells and plasma cells.
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Type 2 macrophage polarization is characterized by suppression of pro-
inflammatory cytokines, intracellular killing and Ag presentation, but accompanied 
by production of moderate levels of IL-10 (Gordon et al. 2003; Martinez et al. 
2009). Membrane receptors with scavenger function are upregulated together 
with a variety of molecules implicated in tissue regeneration, wound healing, 
granuloma formation and immunity against large parasites (Martinez et al. 
2009). Via inducation of arginase 1, arginine metabolism shifts from production 
of NO to production of L-ornithine, utilized to produce polyamines and proline 
important for cell growth and collagen synthesis. M2 macrophages secrete 
chemokines such as CCL17, CCL18, CCL22 and CCL24 which recruit Th2 cells, 
basophils and eosinophils (Mantovani et al. 2004). IgE antibodies produced do 
not fix complement and do not pass placenta and form only 0.05% of serum 
immunoglobulins. However, they are empowered by binding to high affinity 
FcεRI IgE-receptors on the surface of highly explosive MC and basophils.
H4R has been shown in most leukocytes, which are believed to play a role 
in asthma (Gantner et al. 2002). Stimulation of H4R causes MC and eosinophil 
chemotaxis (Hofstra et al. 2003) and increases CD11b/CD18 and ICAM-1 
adhesion molecules on eosinophils (Buckland et al. 2003; Ling et al. 2004; 
Barnard et al. 2008). H4R mRNA has also been shown in non-immune cultured 
cells originating from lung tissue, including smooth muscle cells, epithelial cells 
and vascular endothelial cells. Experimental data suggest that H4R-antagonist 
JNJ 7777120 administered perorally diminishes T cell infiltration into lung 
tissue in already established airway inflammation (Cowden et al. 2010a).
Upon Ag challenge, IL-16 increases in BALF in both patients and experimental 
asthma models. Histamine stimulates production of IL-16 in pulmonary 
epithelial cells and CD8+ T-cells (Cruikshank et al. 2000; Gantner et al. 2002). 
The stimulating effect of histamine on CD8+ T-cells is mediated via H2R and H4R, 
but in asthma most IL-16 is probably derived from epithelial cells. The amount 
of IL-16 in BALF correlates with the CD4+ T-cell infiltrates in asthma (Cruikshank 
et al. 2000). This agrees with the observation that IL-16 binds to the CD4-receptor 
and promotes recruitment of CD4+ cells. In OVA-sensitized mice, intra-tracheal 
administration of IL-16 before OVA challenge lead to inflammatory inilftrates 
and diminished Th2-cytokine IL-5 in BALF (Little et al. 2003). This could be due 
to recruitment and induction of Treg (McFadden et al. 2007).
DCs have a capacity to act in a tolerogenic, anti-inflammatory or pro-
inflammatory way, but the factors regulating the type of DC response are 
not known in detail. Histamine in vitro can stimulate migration of monocyte-
derived cDC via H2R and H4R (Gutzmer et al. 2005). The same study reported 
that stimulation of cDC via H4R inhibited production of Th1-cytokine IL-12 
and therefore promotes Th2-cytokine milieu. Screening of gene expression 
in histamine stimulated cDC demonstrated increased expression of certain 
Th2-related cytokines, such as TNF-α and TGF-β2 (Lundberg et al. 2011). 
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However, histamine stimulation also causes gene expression of various 
chemokines and cytokines that are related to Th1-, Th17- and Treg-mediated 
immune responses. Histamine affected the maturation of DCs via H1R and H4R. 
The neutral H4R-antagonist JNJ7777120 inhibited allergen-provoked T-cells 
in vitro.
Conflicting results have also been published. Inhalation of 4-MeHA, which is 
a double agonist of H4R and H2R (with approximately 100-fold preference for 
H4R) inhibited OVA-induced inflammation, probably due to the Treg recruitment 
to lungs (Morgan et al. 2007) or indirectly via effects on DCs. It is possible that 
this difference is simply caused by a different route of drug application, as 
inhaled 4-MeHA causes a local chemotactic concentration gradient to H4R and 
H2R positive leukocytes, whereas a systemic or genetic inhibition of H4R and H4R 
antagonists directly inhibit H4R
+ cells everywhere (Cowden et al. 2010a; Dunford 
et al., 2006).
7.13. Allergic Rhinitis
Allergic rhinitis, either seasonal or persistent/perennial, is characterized by 
recurrent sneezing, increased mucus production, obstruction of the nasal 
passages and itching. (Skoner et al. 2001). It has a strong genetic component 
favouring development of Th2-IgE-MC-mediated immune responses upon 
challenge and sensitization to allergens. Common allergens are fecal proteins 
from dust mites, cat and dog dandruff and pollen. The central mechanism in 
the sensitization phase is DC-mediated Ag presentation to Th0 cells favoring 
polarization to IL-3, IL-4, IL-5 and IL-13 producing Th2 cells and plasma cell-
mediated production of IgE antibodies. Upon Ag re-challenge nasal mucosal 
membranes become infiltrated by MC, eosinophils and plasma cells. Also 
basophils have been found in nasal lavage fluid in such patients (Shiraishi 
et al. 2013). Local or systemic administration of H1R-antagonists, local 
sympathomimetic drugs (pseudoephedrin) and local corticosteroids are used in 
its treatment.
H1R is expressed on the epithelial, endothelial and neural cells in the 
lower nasal passages, H2R on epithelial and glandular (mucus production) 
cells and both H3R and H4R on neural cells (Nakaya et al. 2004). It has been 
proposed that H3R participates in the homeostatic maintenance of the 
nasal mucosa and regulates mucus production (Suzuki et al. 2008). Phase 
II clinical study did not find any advantage of H1R/H3R antagonist over H1R 
antagonist upon exposure to allergen in a challenge chamber (Daley-Yates 
et al. 2012).
Experimental animal studies showed that repeated local administration of 
H4R-antagonist JNJ7777120 decreased sneezing and scratching of the nose at 
only 1 nM concentration (Takahashi et al. 2009). Repeated peroral administration 
Brought to you by | Università degli Studi di Firenze
Authenticated
Download Date | 11/4/16 12:35 PM
Histamine H4 Receptor:
A Novel Drug Target in Immunoregulation and Inflammation
2 2 8 Chapter 7
decreased serum IgE concentrations while decreased IL-4and increased IFN-γ 
levels were found concurrently in nasal lavage fluid, which is notable because 
IL-4 and IFN-γ increase and decrease plasma cell-mediated IgE production. 
Results encourage to further studies of single or double action drugs.
H4R-antagonists could possibly have symphatomimetic, pseudoefedrin-
like effects via induced endogenous cathecolamine release (Chan et al. 2012). 
Inhibition of H4R with antagonists or gene knockout is antipruritogenic and 
stimulation of H4R with histamine causes itch, with a similar effect obtained 
via manipulation of H1R (Dunford et al. 2007; Thurmond et al. 2008; Rossbach 
et al. 2011). A third possible mechanism of action could relate to diminished 
MC and eosinophil chemotaxis along with diminished DC, Th2 and plasma cell 
dependent IgE synthesis, which would affect both the acute and chronic phase 
of allergic rhinitis.
7.14. Allergic Conjunctivitis
Allergic conjunctivitis is characterized by bilateral itch, burning, redness, tearing 
and swelling of the conjunctiva and lids. Seasonal allergic conjunctivitis (SAC) 
and perennial (persistent) forms (PAC) are relatively mild Ag-driven diseases, but 
atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) can affect 
the cornea and vision (Bonini et al. 2009). Comorbidity between AKC, allergic 
rhinitis, atopic dermatitis, urticaria and asthma is common, suggesting shared 
disease mechanisms in form of sensitization and subsequent challenge phases. 
Although specific allergens cannot be shown in a large proportion of VKC-
patients, inflammation is Th2-driven with increased histamine concentrations 
in tear fluid (Leonardi et al. 2011), which may contribute to pathological tissue 
remodeling and chronicity. As a result, local and peroral H1R-antagonists, mast 
cell-stabilizing drugs (such as cromoglycate and nedochromil) and corticosteroid 
eye drops form the mainstay of treatment (Bonini et al. 2009). In difficult cases, 
immunosuppressive calcineurin-inhibitors and sometimes desensitization can 
improve tolerance to allergens.
Locally administered levocabastine (H1R-antagonist) and JNJ7777120 (H4R-
antagonist) diminished scraping response, hyperemia and swelling in a dose-
dependent manner in a 2-10 μM histamine-induced experimental mouse 
model, but statistical significance was only seen for the H1R-antagonist, but 
the most potent effect was obtained by combined use (Nakano et al. 2009). 
Immunostaining revealed increased H1R, H2R and H4R levels in conjunctival 
cells for VKC patients compared to controls (Leonardi et al. 2011), which was 
confirmed by messenger RNA levels that were 5-fold increased for H2R and 
H4R. H1R was particularly increased on vascular endothelial cells and H4R in 
stromal inflammatory cells. Expectations of H4R-modulators are high but require 
conformation by randomized clinical trials.
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7.15. Rheumatoid Arthritis
Reumatoid arthritis (RA) is a symmetrical autoimmune polyarthritis of usually 
small, peripheral synovial joints associated with rheumatoid factor (RF) and anti-
citrullinated protein antibodies (ACPA). Its midline symmetry and involvement of 
the most densely innervated small peripheral joints (with widest representation 
in hominiculus) has evaded firm explanations, but the most strongly advocated 
theory refers to neurogenic inflammation (Konttinen et al. 1994). This is 
interesting considering the close spatial and functional relationship between 
small peripheral C and Aδ neuropeptide nerves and MC (Hukkanen et al. 1991) 
combined with the presence and role of H3R and H4R in the function of those 
nerves. Furthermore, MCs produce corticotropin-releasing hormone (Kempuraj 
et al. 2004) and respond to it (Cao et al. 2006), suggesting the hypothalamus-
pituitary-adrenal or HPA axis might participate in the pathogenesis of RA similar 
to the arthritis model in Lewis rats (Sternberg et al. 1989).
The fundamental cause of RA is unknown and it has been suggested that the 
triggering stimulus (loss of tolerance) and the perpetuating stimulus (chronicity) 
are different, such as an initial triggering infection causing a mostly continuous 
release of cartilage-derived damage-associated molecular patterns (DAMPs) and 
auto-Ag. In this context, it is interesting to note that in rheumatoid synovitis, 
mature DCs capable of presenting antigen and activated cytokine-producing 
T-cells do not recur to the joint from which all cartilage has been removed in 
association to total joint replacement (Li et al. 2001; Li et al. 2002). 
Synovitis is the best known pathological manifestation of RA, although its 
pathology is also evident in the bone marrow and it can be assumed that the 
preclinical immunological processes occur in the lymphoid organs. Synovitial 
stroma is characterized by the presence of MHC II+ macrophages, specifically 
CD4+ T-cells and plasma cells, but also by DCs, MCs, fibroblasts, endothelial 
cells, adipocytes and peripheral nerve fibers and terminals.  Synovial lining 
is composed of fibroblast-like type B lining cells and macrophage-like type A 
lining cells. Cultured RA (fibroblast-like synoviocytes) contain mRNA coding H1R, 
H2R and H3R but lack H4R coding mRNA (Ikawa et al. 2005) but the presence 
of the H4R protein was detected by double staining in proline-4-hydroxylase-
positive synovial fibroblasts and in CD163+ macrophages (Ohki et al. 2007). 
Current disease intervention is based on commencement of early treatment 
with evidence-based, methotrexate-achored combinations with disease-
modifying anti-rheumatic drugs (DMARDs), modified according to patient 
response (saw tooth principle) and guided by fixed goals using the treat-
to-target (T2T) principles, in modern times strongly supported by biological 
anti-rheumatic drugs (biologicals). Biologicals are highly selective drugs with 
targeting entities such as TNF (infliximab, etanercept, adalimumab, certolizumab 
pegol, golimumab), IL-1 (anakinra), IL-6Rα (tocilizumab), CD80/CD86 co-
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stimulatory molecules (abatacept) or CD20/B-cells (rituximab). Janus kinase 3 
tyrosine kinase inhibitor tofacitinib is the latest newcomer.
Synovitis is characterized by increased numbers of MC, which are also 
located at the site of cartilage destruction in the pannus tissue. However, early 
studies using adjunctive treatment with antihistamines (H1R-antagonists) 
(Wilson 1953) and H2R antagonists (Permin et al. 1981) failed, resulting in the 
relegation of histamine to an epiphenomenon rather than active molecular 
participant.
It was therefore notable that inhibition of c-kit tyrosine kinase, typically 
present in MCs, diminished disease activity including the number of tender 
and swollen joints, ESR and CRP (Eklund & Joensuu 2003). C-kit is a tyrosine 
kinase receptor (mast/stem cell growth factor receptor) for stem cell factor 
(SCF), previously annotated as Steel factor or kit-ligand.
In spite of early observations suggesting increased plasma and in particular 
synovial fluid histamine levels, implying intra-articular release (Frewin 
et al. 1986), a more recent finding suggests decreased plasma levels and 
significantly decreased synovial fluid levels of histamine (Adlesic et al. 2007). 
RA serum histamine was 0.93± 0.16 ng/mL compared to 1.89 ± 0.45 ng/mL in 
controls (p<0.001) and the RA synovial fluid histamine levels were only 0.37 ± 
0.16 ng/mL (p<0006). Histamine levels increased in aTNF-treated RA patients 
(p<0.01). These authors also injected 20 µL fluid containing 10, 1, 0.1 or 
0.01 ng histamine intra-articularly into healthy joints or joints challenged with 
a preceding intra-articular injection of high mobility group box-1 (HMGB1, 
an endogenous DAMP) or peptidoglycan (a pathogen/microbial-asssociated 
danger signal, PAMP/MAMP). Histamine produced no effects by itself or in 
induced arthritis. This led the authors to propose that histamine lacks harmful 
properties in RA (Adlesic et al. 2007).
What is clear from the above experiments is that histamine levels in RA are 
at nanomolar levels (0.11 ng/mL histamine corresponds to 1 nM) and 10-8.1 M
histamine is sufficient to half-maximally activate H4R. MC activation may 
locally and temporarily increase histamine levels to micromolar concentration 
range, but due to histamine degradation, uptake, binding and diffusion this 
increase is transient. In contrast, how the low but constitutitively present 
nanomolar histamine levels rather than micromolar levels affect processes 
such as DC0 and Th0 cell polarization and Ag presentation in RA remain open 
at present. In RA tissues, CD304+ (BDCA4) pDCs producing IL-18 and IFN-α/β 
are more common than CD1c+ (BDCA1) cDCs expressing IL12 and IL-23 and 
their numbers correlate with RF and ACPA (Lebre et al. 2008). Indeed, pDCs 
express H4R. H4R-agonists diminished pDC mediated TFN-α, IFN-γ and CXCL8 
production. H2R had similar effects, but it is not known whether the histamine 
levels in RA joints reach H2R-stimulatory concentrations (Gschwandtner et al. 
2011).
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7.16. SLE
Systemic lupus erythematosus (SLE) is a systemic autoimmune and immune 
complex disease in which clearance of immune complexes and apoptotic cell 
rests seems to be impaired with nuclear auto-Ags being especially targeted. 
American College of Rheumatology classification criteria define 12 different 
symptoms and signs where if at least four of these symptoms are positive, the 
condition can be classified as SLE (Hochberg 1997).
HRH4 gene transcripts (H4R coding mRNA) were high in SLE compared to 
healthy controls. Interestingly, amplification in HRH4 copy numbers (>2 HRH4 
copies) was associated with increased incidence of anti-nuclear antibodies, 
arthritis and proteinuria, whereas copy number deletions (<2 HRH4 gene copies) 
were found to be protective against proteinuria (Yu et al. 2010). This seems to 
demonstrate the influence of gene copy-number variation (CNV) on the disease 
phenotype. In SLE, an increased HRH4 gene copy number seems to lead to 
higher H4R mRNA copy numbers, which can cause disturbances in the nanomolar 
histamine-H4R interactions which subsequently affect the disease severity. 
7.17. Sjögren’s Syndrome
Sjögren’s syndrome (SS) is a female dominant (90%) autoimmune disease of the 
exocrine glands, which can occur in primary form but also as a secondary form 
in disorders such as RA and SLE. It is characterized by keratoconjunctivitis sicca 
and xerostomia in association with focal sialadenitis and SS-autoantibodies 
(Shiboski et al. 2012). 
It is well known that local sialadenitis and local numbers of MC correlate to 
each other in SS salivary glands (Konttinen et al. 1990). At that time, histamine 
was expected to perhaps play a role via H1R and/or H2R, although it had earlier 
been shown that intra-arterial injection of 100 nM histamine causes an early, 
short-term (~60 s) increase in blood flow and salivation, followed by a later, 
longer lasting (15-20 minutes) response, which was partially inhibited by H1R-
antagonist but not affected by H2R-antagonist and was found to be neutrally-
mediated without any direct effect on acinar cells (Shimizu & Taira 1980).
More recently, H4R were found on some infiltrating leukocytes as well as acinar 
and ductal epithelial cells in healthy human salivary glands. In contrast, H4R 
expression on these glandular cells was highly decreased in SS (Stegaev et al. 2012), 
suggesting that this epithelial H4R downregulation is due to repeated exposure 
to micromolar, burst release histamine in diseased SS salivary glands. This may 
also explain the relatively weak H4R expression in the infiltrating lymphocytes. 
Epithelial H4R was shown at the mRNA, receptor protein and functional level and it 
seems that these cells are non-professional histamine producing cells containing 
74-kDa HDC, which may participate in the modulation of the off-state nanomolar 
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histamine concentrations apparently necessary for the tissue homeostasis. 
Furthermore, acinar and ductal epithelial cells contained OCT3, which seems to 
allow histamine uptake for intracellular degradation at 100 nM concentrations but 
also allows intracellular histamine release during off-state. In SS, OCT3 levels were 
low, suggesting that the cells are incapable of buffering against burst-released 
histamine, which would partially explain the local downregulation of H4R on 
resident and immigrant cells (Stegaev et al. 2013).
7.18. Ulcerative Colitis
Ulcerative colitis (UC) is an IBD considered as an autoimmune disease, in part 
because of several disease-activity-associated or independent extra-intestinal 
autoimmune manifestations and the immunosuppressive treatment used in 
the disease management. It affects the colon by causing superficial Th2 helper 
T-cell-dominated mucosal infiltrates, inflammatory cryptitis and ulcerative 
lesions. Th17 helper T-cells might also participate. Upon increasing severity, the 
number of blood and mucus mixed stools per day increases, malaise, fatige and 
fever appear as general symptoms, the inflammatory parameters CRP and ESR 
increase and blood hemoglobin decreases, possibly resulting in toxic megacolon 
and rupture. Although basically affecting the colon, some back-wash ileatitis 
often also occurs.
In a steroid-resistent UC, a combination of H1R-antagonists, MC stabilizers and 
a hypoallergenic diet have been preliminarily found to be useful and suggest 
a role for burst release histamine in severe disease and disease exacerbation 
(Raithel et al. 2007). ECL cell and MC-derived histamine is supposed to play an 
important role in the initial increase of the vascular permeability characteristic 
for UC (Coron et al. 2012). Urinary secretion of the HNMT-produced histamine 
degradation product N-methylhistamine is increased in UC and Crohn’s disease 
and correlates with disease activity (Winterkamp et al. 2002). Polymorphic, 
mutated DAO is associated with the severity of UC (García-Martin et al. 2006). 
Disturbances in nerve-derived and bacterially-produced histamine may further 
disturb the local histamine milieu and interfere with DC-T-cell co-operation but 
also with angiogenesis and fibrosis. H4R antagonists diminished macroscopic 
damage, myeloperoxidase, TNF-α, wall thickness and neutrophil infiltratation 
when administered 24 hours before induction of an acute colitis model in rats 
using exposure to trinitrobenzene sulphonic acid (Varga et al. 2005).
7.19. Crohn’s Disease
Crohn’s disease was earlier called terminal ileitis due to the common involvement 
of this segment of the intestine. However, this disease can affect any part of the 
human gastro-intestinal tract, often as skip lesions with intact and apparently 
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uninvolved bowel segments in between the focal and segmental leasions. 
Crohn’s disease is characterized by abdominal pain, weight loss, fever, diarrhea, 
transmural involvement of the bowel wall (with peri-intestinal abscesses, fistuli 
and bowel stenosis. and extra-intestinal symptoms as well as anti-inflammatory 
and immunosuppressive medication. Its histology is characterized by intraepithelial 
neutrophils, cryptitis, Th1/Th17 response and non-caseating granulomas. Although 
H4R is supposed to play a role in the regulation of the polarization of Th0 cells, there 
is at present little knowledge on this aspect in Crohn’s disease. Interactions between 
PAMP/MAMP and bacterial Ags with DCs and their subsequent interactions with Th0 
T-helper cells have been proposed to regulate the balance between Treg and Teff in a 
context-dependent manner in IBD (Himmel et al. 2008).
The H1R-agonist HTMT-dimaleat, H2R-agonist dimaprit, H3R-agonist (R)-(-)-α-
methylhistamine and H4R-agonist 4-methylhistamine can excite enteric neurons 
in human submucosal plexus, where the receptor specificity of this excitation was 
proven by demonstrating blockage with a corresponding antagonist. Considering 
the role of the autonomic enteric nerves of the intestine as regulators of the 
bowel function, this implies a novel and interesting aspect for IBD (Breunig et 
al. 2007) and emphasizes the role of the neuro-immuno-endocrine aspects of 
autoimmune diseases (Lomax et al. 2005; Wood 2004). 
In addition to nerves, H1R, H2R and some H4R have been described in 
enterocytes, H1R and H2R in muscle layer and H1R, H2R and some H4R in immune 
cells (Sander et al. 2006).
7.20.Glomerulonephritis
One rare form of rapidly progressive glomerulonephritis is the anti-glomerular 
basement membrane-induced Goodpasture’s syndrome. An experimental model 
of Goodpasture’s syndrome can be treated with histamine, which decreased 
proteinuria, macrophage infiltration and crescent formation. It also decreased 
concentrations of IL-12, a well-known Th1 polarizing cytokine. These effects 
were specifically inhibited by an H4R-antagonist but not affected by H1R- and 
H2R-antagonists (Tanda et al. 2007), although an earlier study published when 
only H1R and H2R were known used only H1R- and H2R-antagonists and argued 
that histamine plays no role in Goodpasture’s syndrome (Wilson et al. 1981). 
This once more reveals how earlier work needs to re-evaluated in light of new 
findings. There are currently no observations on H4R status and function in the 
more common forms of glomerulonephritides.
7.21. Autoimmune Diseases of the CNS
Several lines of evidence suggest a key regulatory role of histamine in the 
widely used experimental autoimmune encephalomyelitis (EAE) murine model, 
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with CNS myelin proteins as potential auto-Ags (Musio et al. 2006; Lu et al. 
2010; Passani & Ballerini 2012). Therefore, the regulatory functions of histamine 
relevant to the onset and progression of neuroinflammatory diseases and EAE 
in particular are being studied in genetically modified mice lacking histamine 
receptors and with selective agonists and antagonists. It is becoming evident 
that histamine plays a complex role with variable and occasionally contradictory 
effects, depending on the receptor subtypes being activated and the specific 
targeted tissue (Table 7.2).
All histamine receptors are expressed on cells involved in autoimmune 
diseases, with the exception of the H3R that is normally not expressed by 
hematopoietic cells and is mostly confined to the CNS (Passani & Blandina 
2011). Susceptibility to EAE requires expression of Hrh1, the gene encoding H1R 
in mice (Ma et al. 2002). H1R is expressed on Th1 cells in EAE mice brain lesions 
(Pedotti et al. 2003) where its presence is necessary for full encephalitogenic 
expression (Noubade et al. 2007). Furthermore, expression of H1R is upregulated 
on encephalitogenic PLP139-151-specific Th1 compared to Th2 cell lines. 
Unsurprisingly, specific pharmacological antagonists targeting H1R result in 
amelioration of EAE (Pedotti et al. 2003; El Behi et al. 2007) and H1R-knockout 
mice exhibit a significant delay in the onset of EAE and a reduction in the 
severity of clinical signs compared with WT mice. Indeed, CD4+ T-cells from H1R-
knockout mice produce significantly less IFN-γ and more IL-4 (which induces 
differentiation of naïve CD4+ T cells to Th2 cells) in in vitro assays compared to 
wild-type controls, indicating that H1R signaling in CD4
+ T cells plays a central 
role in regulating pathogenic T-cell responses (Ma et al. 2002).
H2R also seems to partially regulate encephalitogenic Th1-cell responses and 
EAE susceptibility, as H2R-knockout mice develop a less severe disease than 
wild-type littermates during the acute, early phase (Teuscher et al. 2004). The 
failure of H2R-knockout mice to generate encephalitogenic Th1 effector cell 
responses is attributed to H2R-mediated regulation of cytokine production by 
DCs, which affects T-cell-polarizing activity. In conclusion, H1R and H2R seem to 
have pro-inflammatory and disease-promoting effects, but H1R or H2R activation 
may also play an important role in limiting autoimmune responses, meaning their 
biological action is probably more complex. This complexity is further suggested 
in an EAE mouse model, where H1R and H4R produced pro-inflammatory effects 
but H2R and H3R produced anti-inflammatory effects on the disease process 
(Jadidi-Niaragh & Mirshafiey 2010).
As mentioned above, H3R are normally not expressed by hematopoietic cells 
and are mostly confined to the CNS where they limit histamine synthesis and 
release (Passani & Blandina 2011), and regulate release of other neurotransmitters 
(Blandina et al. 2010). Deletion of the H3R gene leads to more severe EAE, an 
effect associated with altered BBB permeability and increased expression of 
chemokines/chemokine receptors that promote the entry of peripheral T cells 
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not expressing H3R into the CNS (Teuscher et al. 2007). The authors suggest 
that neuronal H3R may serve as a central control of cerebrovascular tone and 
decreases susceptibility to neuroinflammatory diseases. These results indicate 
that activation of H3R may have beneficial effects.
Recent evidence has mapped the topological and functional localisation 
of H4R in the CNS of humans and rodents, respectively (Strakhova et al. 2009; 
Connelly et al. 2009). 
H4R is detected on hematopoietic progenitor cells that enter the cell cycle 
upon stimulation (Petit-Bertron et al. 2009). Activation of H4R by agonists before 
exposure to growth factors leads to a profound decrease in the percentage 
of cycling cells (Schneider et al. 2011). The H4R expression is dynamic, as it is 
upregulated during the differentiation of human monocytes to dendritic cells 
(Gutzmer et al. 2005). In addition, receptor levels change with the progression 
of pathophysiological responses, such as the upregulation of H4R expression in 
monocytes in response to inflammatory stimuli (Dijkstra et al. 2007), in kidney 
putative tubule cells in diabetic rats (Chazot, Rosa et al., manuscript submitted) 
and in putative immune cells at the early stage of inflammatory pain states 
(Chazot et al., unpublished). Furthermore, pilot data revealed that H4Rs are 
expressed on the soma of both Aδ and C-fibre sensory neurons through intense 
staining of small and medium diameter neurons as well as lamina I-III of the rat 
lumbar spinal cord, where the immunoreactivity pattern suggests localisation 
with terminals of primary afferent neurons (Katebe M et al. 2012; Lethbridge & 
Chazot 2010). 
Surprisingly, H4R-knockout mice develop a more severe EAE together with 
increased neuroinflammatory signs compared to WT mice (del Rio et al., 2012). 
As genetically modified mice may carry alterations of systems other than the 
targeted ones and activation of vicarious mechanisms may hinder the effects 
related to the deleted gene, we recently studied myelin oligodendrocyte 
glycoprotein (MOG)35–55-induced EAE in C57BL/6 mice treated with JNJ-7777120 
(Ballerini et al., submitted to Br J Pharmacol). JNJ-7777120 was injected i.p. 
daily starting at day 10 post-immunisation. Disease severity was monitored by 
clinical and histopathological evaluation of inflammatory cells infiltrating into 
the spinal cord, anti-MOG35-55 antibody (Ab) production, T cell proliferation by 
[3H]-thymidine incorporation, mononuclear cell phenotype by flow cytometry, 
cytokine production by ELISA assay and transcription factor quantification by 
mRNA expression. We found that treatment with JNJ-7777120 worsened the 
severity of EAE and increased inflammation and demyelination in the spinal cord 
of EAE mice. We also showed that during disease progression, T lymphocytes of 
JNJ-7777120-treated EAE mice produce more IFN-γ than vehicle-treated controls 
and fewer regulatory cytokines such as IL-4 and IL-10, despite unchanged 
frequency and proliferative capacity in response to MOG35-55. Furthermore, 
JNJ-7777120 did not affect anti-MOG35-55 Ab production or mononuclear cell 
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phenotypes. Hence, our results are in agreement with the recent report that mice 
which do not express H4R exhibit an exacerbated disease and immunopathology 
(del Rio et al. 2012). This was ascribed to impaired formation of Treg T-cells and 
their impaired chemotaxis and suppressor activity, leading to an increase in the 
Th17 T-cells.
7.22. Future Visions
Histamine is produced slowly by 73-kD HDC and released gradually via OCT2/3 
and PMAT ion channels without storage phase by non-professional histamine-
producing cells at low nanomolar concentrations, which only affect the high 
affinity H3R/H4R-equipped DCs, T-cells and other leukocytes. 
This basal level H3R/H4R effect is during the resting “off-state” probably 
maintained within narrow limits by the high constitutive activation state of 
H3R/H4Rs, histamine produced by non-professional cells, histamine released 
by professional cells, histamine produced by intestinal microflora on one 
hand, and by the DAO-mediated extracellular and HNMT-mediated intracellular 
degradation as well as VMAT-mediated re-uptake and storage.
As this “off-state” appears to be prevailing in healthy individual during most 
of the time, it can be assumed that it participates in DC-T-cell interactions by 
favouring maintenance of tolerance, i.e. contributing to the active tolerogenic 
immune responses against self-Ag, which leads to production of iTreg cells.
If a foreign Ag and an adjuvant (danger signal) are introduced to the system, 
in the context of danger a immunogenic response is produced, which leads to 
production of Teff cells and provision of T-cell help to B-cells, which initiates T-cell-
dependent, B-cell-mediated immune responses and production of antibodies. If 
directed against a transient foreign pathogen or vaccine, this provides immunity. 
If however this immune activation occurs against continuously present self-Ag, 
an autoimmune disease ensues.
Immediate type I immune responses cause a lot of morbidity in form of 
allergic responses and diseases. These diseases are mediated by professional 
histamine-producing cells, such as MCs and basophils. However, type I immune 
responses are only possible after the sensitization phase, which required cell-
mediated, delayed type immune responses and production of MC/basophil-
sensitizing IgE. When the IgE-sensitized MCs and basophils degranulate and 
release their stored histamine, short-term and locally high micromolar histamine 
concentrations are attained during an “on-state”. The concentrations are high 
enough to activate the low affinity H1R/H2Rs. 
Non-immune activation of MCs and basophils might in healthy individuals 
occur as a result of local irritation, in particular in sensitive mucosal surfaces 
or where the skin is penetrated, leading to a local reaction helping to get rid 
of or to dilute the local irritant. Autoinflammatory responses evoked by danger 
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signals, viz. pathogen/microbe-associated molecular patterns and/or damage-
associated molecular patterns (or alarmins), might enhance this non-immune 
responsiveness of tissues. If the exposure continues, these naïve responses are 
after sensitization enhanced by immediate type I hypersensitivity responses.
It is commonly accepted that in the treatment of these allergic diseases, 
if possible, elimination of the allergen by sanitary measures is an effective 
and logic form of intervention. In both autoimmune diseases and in allergic 
disease modulation of the DC-T-cell interactions seems to be a useful roadmap 
to new therapies. Induction of immune tolerance and a shift from IgE to IgG 
production seem to be tempting therapeutic targets. Due to the putative role 
of low nanomolar histamine and high-affinity H3R/H4Rs, modulation of these 
interactions by systemic and/or local synthetic small molecular weight H3R- and 
H4R-modulators to prevent sensitization or to induce tolerance seems to be the 
way to go. They good replace the currently widely used and expensive biologic 
drugs and biosimilars, which usually influence down-stream effector effects, for 
example by neutralizing pro-inflammatory cytokines, and extend the spectrum of 
non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids to biologic 
anti-inflammatory drugs. Interventions targeting more proximal pathogenic 
events at the root of the disease, treating the cause rather than the symptoms, 
seem more logical. The clinical and commercial success of antihistamines and 
H2R blockers encourage further research of H3Rs and H4Rs.
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